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Abstract
Background: Standardization of trans-bronchial lung cryobiopsy in diffuse parenchymal lung diseases is imminent;
however, the majority of published series on cryobiopsy include a limited number of patients and are characterized
by several differences in procedural technical details.
Methods: This is an observational, retrospective cohort study. Aim of the study was to suggest some sampling
strategies related to transbronchial cryobiopsy in the diagnostic work-up of patients with diffuse parenchymal lung
diseases.
Results: Six hundred ninety-nine patients with suspected diffuse parenchymal lung disease were recruited. A specific
pathological diagnosis was achieved in 614/699 cases (87.8%) and a multidisciplinary diagnosis was obtained in 630/
699 cases (90.1%). Diagnostic yield was significantly influenced by the number of samples taken (1 vs≥ 2 biopsies,
p < 0.005). In 60.4% of patients, biopsies were taken from one site and in 39.6% from different sites (in the same lobe or
in two different lobes), with a significant increase in diagnostic yield, specifically in patients with fibrotic lung diseases
(65.5% vs 93.4%, p < 0.0001). The 2.4 mm or 1.9 mm probes were used, with no differences in terms of diagnostic yield.
Regarding safety, pneumothorax occurred in 19.2% and was influenced by baseline lung function; in all patients
Fogarty balloon has been used and severe haemorrhage occurred in 0.7% of cases. Three patients (0.4% of cases) died
within 30 days after the procedure.
Conclusions: We propose some sampling strategies of cryobiopsy which seem to be associated with a higher
diagnostic yield and a favorable risk/benefit ratio: sampling at least two samples in different sites, using either the 2.4
mm or the 1.9 mm probe, intubating the patients and using bronchial blockers/catheters.
Keywords: Cryobiopsy, Transbronchial lung cryobiopsy, TLCB, ILD, Interstitial lung disease, DPLDs, Diffuse parenchymal
lung disease, IPF, Idiopathic pulmonary fibrosis
* Correspondence: claudiaravaglia79@gmail.com
1Department of Thoracic Diseases, G.B. Morgagni - L. Pierantoni Hospital, Via
C. Forlanini 34, 47121 Forlì, FC, Italy
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ravaglia et al. BMC Pulmonary Medicine           (2019) 19:16 
https://doi.org/10.1186/s12890-019-0780-3
Background
While standardization of the cryobiopsy in the diagnos-
tic process of diffuse parenchymal lung diseases is
imminent, series reporting experience of cryobiopsy gen-
erally include limited number of patients. It is difficult
to compare series due to differences in sampling strat-
egies and procedural technical details (such as the use of
bronchial blockers to minimize haemorrhage), resulting
in major differences in the diagnostic yield and preva-
lence of complications. We report the largest series of
patients with suspected diffuse parenchymal lung disease
undergoing transbronchial lung cryobiopsy and we
propose a sampling strategy which is associated with a
high diagnostic yield and a favorable risk/benefit ratio.
Methods
We identified from our database all subjects who had
undergone trans-bronchial lung cryobiopsy (TLCB) at
the Pulmonology Unit of G.B. Morgagni – L. Pierantoni
Hospital in Forlì (Italy) for diagnosis of diffuse parenchy-
mal lung diseases from March 2011 through September
2017. All subjects had suspected diffuse parenchymal lung
diseases with non-diagnostic clinical profiles, CT scan
features (either fibrotic or non-fibrotic), and laboratory
tests (including autoimmune serology and precipitins) for
whom a biopsy was deemed useful for a diagnosis were
prospectively enrolled.
Bronchoscopies were performed as previously described
[1]: a 1.9 mm or 2.4mm cryoprobe was used (ERBE,
Germany) and patients were deeply sedated (using propo-
fol and remifentanil), maintained in spontaneous breath-
ing and intubated with a rigid tracheoscope. Biopsies were
obtained under fluoroscopic guidance at a distance of ap-
proximately 10mm from the thoracic wall. Bronchoscopic
cryobiopsy was targeted to the areas of abnormality seen
on HRCT (high resolution computed tomography), with
samples taken from one site or multiple sites depending
on the radiological pattern and distribution of disease; in
particular, cryobiopsy was performed in different sites in
patients with significant radiographic inter-lobar hetero-
geneity, while in patients with diffuse radiographic pattern
(both in the upper and the lower lobes) or in patients with
a significant apical-basal gradient cryobiopsy was more
frequently performed in the same lobe. The choice of the
site and side of biopsy was decided upon before the pro-
cedure. Biopsies obtained from the middle lobe and the
lingula were included in the analysis and compared for
both diagnostic yield and complications (being excluded
only in the specific analysis evaluating the differences be-
tween upper lobes and lower lobes). The probe was cooled
for approximately 5–6 s or 7–8 s for the 2.4mm and 1.9
mm diameter respectively. The frozen specimens were
thawed in saline and then transferred gently to formalin
for fixation. A Fogarty balloon was always routinely used
to prevent severe bleeding. As previously described [2],
bleeding was defined as “mild” if requiring just endoscopic
aspiration, “moderate” if requiring further endoscopic pro-
cedures (bronchial occlusion and/or instillation of ice-cold
saline), and “severe” if requiring surgical interventions,
transfusions and/or admission to intensive care unit for
hemodynamic or respiratory instability. Within 3 hours of
the procedure, a chest radiograph was performed to assess
for pneumothorax.
In the first 310 of this series, specimens were
reviewed by three expert lung pathologists (AD, AC
and TVC); the remaining cases were reviewed by AD
and AC and only in case of discordancy, a consensus
diagnosis was reached after consultation with a third
pathologist (TVC).
Biopsies were considered “non diagnostic” when his-
topathologic criteria sufficient to define a characteris-
tic histopathologic pattern were lacking (eg. normal
lung or minimal nonspecific changes) or when
samples were considered inadequate (eg, too small or
airway wall with no alveolated lung parenchyma).
Clinical information, radiological features and biopsy
results were then reviewed by clinicians, radiologist
and pathologists and a multidisciplinary diagnosis was
made, with cryobiopsy considered diagnostic if add-
itional evaluation, including surgical lung biopsy, was
considered to be unnecessary.
Statistical analysis
Statistical analyses were performed using Fisher exact test,
Mann-Whitney U test and univariate/multivariate Cox re-
gression analyses; SPSS statistics and STATA (version 12,
StatCorp, College Station, TX, USA) were used. A p value
of < 0.05 was considered statistically significant.
Results
During the study period, 699 subjects with a median age
of 61 ± 11 years underwent cryobiopsy for evaluation of
diffuse parenchymal lung disease. Some of these patients
have been included in other published series relating to
transbronchial lung cryobiopsy [1–4]. Subject character-
istics are summarized in Table 1. In 422 patients
(60.4%), biopsies were taken from one site, in 267 pa-
tients (38.2%) from two sites and in 10 cases (1.4%) from
three different sites. Different sites were represented by
different segments of the same lobe (in 166 cases) or
segments of two different lobes (in 101 cases). Average
number of fragments was 3.3 (range 1–11). 2.4 mm
probe has been used in 613 patients and 1.9 mm probe
has been used in 73 patients (in cases when excessive re-
sistance during retrieval of the 2.4 mm probe was ob-
served due to bronchomalacia or when sampling in the
upper lobes with the 2.4 mm probe was particularly diffi-
cult). Pleural tissue was detected in 177 cases (25.3%).
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Mean surface of samples was 30, 35 mm2 +/− 18,4 (range
1,51 – 392,4). Biopsy characteristics are summarized in
Table 2.
A specific pathological diagnosis was achieved in 614/
699 cases (87.8%). The pathologic interpretations are
shown in Table 3, including 262 (37.5%) UIP (usual
interstitial pneumonia), 66 (9.4%) NSIP (non-specific inter-
stitial pneumonia) or OP/NSIP (organizing pneumonia/
non-specific interstitial pneumonia), 58 (8.3%) OP (organiz-
ing pneumonia), 36 (5.2%) DIP/RB-ILD (desquamative
interstitial pneumonia/respiratory bronchiolitis-interstitial
lung disease), 47 (6.7%) malignancy, 38 (5.4%) sarcoidosis,
33 (4.7%) HP (hypersensitivity pneumonitis) and 21 bron-
chiolitis (3.0%). Among patients with UIP pattern on bi-
opsy, in 58% of cases the pathological diagnosis of UIP was
done with high level of confidence (patchy fibrosis and fi-
broblastic foci with or without honey-combing and no an-
cillary findings against IPF). When histology has been
reviewed by three pathologists, the overall interpersonal
Table 1 Clinical characteristics, diagnostic yield and complications
in patients submitted to trans-bronchial lung cryobiopsy (TLCB)
Patient characteristic (tot 699) No. (% or SD)
Median age (SD), y 61 (11)
Male, No. (%) 413 (59.1%)
Mean FVC percent predicted (SD) 85.4 (19.7)
Mean DLCO percent predicted (SD) 61.2 (17.5)
Pathological diagnosis, No. (%) 614 (87.8)
Multidisciplinary diagnosis, No. (%) 630 (90.1)
Pneumothorax, No. (%) 134 (19.2)
Drained Pneumothorax (among
those with pneumothorax), No. (%)
94 (70.1)
Mild bleeding, No. (%) 29 (4.1)
Moderate bleeding, No. (%) 53 (7.6)
Severe bleeding, No. (%) 5 (0.7%)
Abbreviations: FVC Forced vital capacity, DLCO Diffusing capacity of the lungs
for carbon monoxide
Table 2 Biopsy characteristics and sampling strategy in patients
submitted to trans-bronchial lung cryobiopsy (TLCB)
Biopsy characteristics No. (% or range)
Number of samples 3.3 (1–11)
Probe size
- 2,4 mm - 613 (87.7%)
- 1,9 mm - 73 (10.4%)





- One site - 422 (60.4%)
- Two different sites - 267 (38.2%)
- 166 same lobe
- 101 different lobes
- Three different sites - 10 (1.4%)
Cryobiopsy smallest axis
diameter









Sample surface area 30.35 mm2 +/− 18.4
(range 1,51–392.4)
Table 3 Histopathologic pictures of patients undergoing trans-
bronchial lung cryobiopsy
Morphological diagnosis No. (%)
UIP pattern 262 (37.5%)
- 236 UIP
- 7 UIP + PPFE
- 19 UIP-HP
HP pattern 33 (4.7%)
- 31 HP























- 2 GL-ILD a
- 2 Lymphoid Nodular
Hyperplasia






Abbreviations: UIP Usual interstitial pneumonia, PPFE Pleuro-parenchymal
fibroelastosis, HP Hypersensitivity pneumonitis, OP Organizing pneumonia,
NSIP Non-specific interstitial pneumonia, DIP Desquamative interstitial
pneumonia, RB-ILD Respiratory bronchiolitis-interstitial lung disease, LCH
Langerhans cell histiocytosis, DAD Diffuse alveolar damage, AFOP Acute
fibrinous organizing pneumonia, GL-ILD Granulomatous lymphocytic-interstitial
lung disease, DIPNECH Diffuse idiopathic pulmonary neuroendocrine cell
hyperplasia, ACFE Airway-centered fibroelastosis, ECD Erdheim Chester disease.
aDiagnosis based on clinicopathologic correlation
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agreement between pathologists for the diagnosis of UIP
pattern was 0.72 (0.64–0.80) and the overall agreement for
the level of confidence in the diagnosis of UIP pattern was
0.54 (0.45–0.62).
A multidisciplinary diagnosis was possible in 630/699
cases (90.1%). The most common diagnosis (245/699)
was UIP/IPF (idiopathic pulmonary fibrosis). Other diag-
noses are displayed in Table 4. In the remaining 20
patients (2.9%), disease was considered to be unclassifi-
able. Among the 69 subjects with non-diagnostic or un-
certain cryobiopsies, 4 patients repeated cryobiopsy
(final diagnoses were 1 alveolar proteinosis, 1 IPF, 1
lymphoma and 1 confirmed ACFE = airway centered
fibroelastosis), 38 patients (5.4%) underwent surgical
lung biopsy (diagnoses were 1 COP = cryptogenic OP, 16
IPF, 1 vasculitis, 1 cocaine-lung, 3 chronic HP, 1 con-
firmed ACFE, 1 confirmed ECD = Erdheim Chester dis-
ease, 4 diffuse lung cancer, 3 iNSIP, 2 RB-ILD, 1
lymphoma, 1 Langerhans cell Hystiocytosis, 1 alveolar
proteinosis, 1 CTD-ILD = connective tissue disease re-
lated ILD, 1 diffuse inflammatory myofibroblastic
tumour), 6 patients underwent CT-guided percutaneous
lung biopsy (diagnoses were 3 diffuse lung cancer, 1
lymphoma, 1 COP, 1 not diagnostic) and 1 patient
underwent surgical mediastinoscopy (sarcoidosis).
Yields for both pathological and final multidisciplinary
diagnoses were influenced by the number of samples
taken. After a single biopsy, the diagnostic yield was
67.6%, rising strikingly with a second biopsy to 91 and
87% for pathological and multidisciplinary diagnosis re-
spectively. The diagnostic yields did not increase further
if more than two samples were taken (Table 5). The
diagnostic yield was also influenced by the sampling
strategy: yields of both pathological and multidisciplinary
diagnoses were significantly increased when biopsies
were taken from two sites instead of only one site (247/
267, 92.5% vs 358/422, 84.8%, p = 0,001 and 248/267,
92.9% vs 373/422, 88.4%, p = 0,043 respectively) (Table 6),
although yields did not differ whether sites were repre-
sented by different segments of the same lobe (eg pos-
terior and lateral segment of the right lower lobe) or
segments coming from different lobes (eg. right lower
lobe and right upper lobe) (Table 6). Specifically, consid-
ering only patients with fibrotic lung diseases undergo-
ing cryobiopsy in two sites (n = 197), the diagnostic yield
from a single site was 65.5%, increasing to 93.4% with
sampling from a second site (p < 0.0001). Samples from
two sites were considered concordant if they showed the
same pattern (eg, UIP pattern in the lower lobe and UIP
pattern in the upper lobe) and discordant if they showed
different patterns (eg, NSIP in the upper lobes and UIP
in the lower lobes); cases in which the biopsy was inad-
equate or non-diagnostic in both sites were excluded.
Discordant samples between the two sites were observed
in 55 patients (27.9%). As shown in Table 6, diagnostic
yield did not differ between the 1.9 mm and 2.4 mm
probes. These results were confirmed following correc-
tion for sampling strategy and number of samples taken
(probe size: odds ratio 1.48, p-value = 0.277, CI 95.0%
0.73–3.00; samples number: odds ratio 3.65, p-value =
0.001, CI 95.0% 1.65–8.07; sampling strategy: odds ratio
1.82, p-value = 0.046, CI 95.0% 1.01–3.26).
Table 4 Final multidisciplinary diagnoses in patients
undergoing trans-bronchial lung cryobiopsy (TLCB)
Multidisciplinary diagnosis No. (%)
IPF 245 (35.1%)
- 229 sporadic IPF
























- 2 lymphoid nodular
hyperplasia in CVID
- 2 GL-ILD








Abbreviations: IPF Idiopathic pulmonary fibrosis, CTD Connective tissue
disease, COP Cryptogenic organizing pneumonia, HP Hypersensitivity
pneumonitis, RB-ILD Respiratory bronchiolitis-interstitial lung disease, iNSIP
Idiopathic, NSIP Non-specific interstitial pneumonia, DR-ILD Drug-related
interstitial lung disease, LCH Langerhans cell histiocytosis, iPPFE Idiopathic
pleuro-parenchymal fibroelastosis, CEP Chronic eosinophilic pneumonia, AFOP
Acute fibrinous organizing pneumonia, GVHD Graft versus host disease, CVID
Common variable immune-deficiency, GL-ILD Granulomatous lymphocytic-
interstitial lung disease, DAD Diffuse alveolar damage, ACFE Airway-centered
fibroelastosis, ECD Erdheim Chester disease
Ravaglia et al. BMC Pulmonary Medicine           (2019) 19:16 Page 4 of 10
Safety outcomes are summarized in Table 7. Pneumo-
thorax occurred in 134 patients (19.2%), requiring
chest-tube drainage in 94 cases (70.1%). The risk of
pneumothorax was increased when samples were taken
from different sites (p = 0,002), from the lower lobes (p
0,00004) and with the use of the 2.4 mm probe (p <
0,0001) (Table 6); it was also related with the numbers
of samples (p 0,0009) (Table 5) and the lung function
impairment (forced vital capacity, FVC: p = 0,0079; dif-
fusing capacity of the lungs for carbon monoxide,
DLCO: p = 0,0331, Table 8). Moderate haemorrhage was
observed in 53 patients (7.6%) and severe haemorrhage
in 5 patients (0.7%). There were no cases of fatal haem-
orrhage. The frequency of haemorrhage was not related
to the sampling strategy (episodes of bleeding were simi-
lar if performing cryobiopsy in one site or multiple sites,
both in one lobe or different lobes) (Table 6), the probe
size (p 0,6460) or the severity of lung function
impairment (as judged by FVC and DLCO levels). How-
ever, there was an increased risk of haemorrhage from
biopsies performed in the lower lobes (p = 0,027). It was
not possible to correlate the bleeding incidence with the
number of samples as, after the bleeding occurred, the
procedure was usually interrupted, therefore the number
of samples is significantly reduced in the group of pa-
tients who developed bleeding during cryobiopsy. Inci-
dence of moderate/severe bleeding after first sample was
15/34 (44%); moderate/severe bleeding occurring after
the second sample was 13% (17/134 cases). Three pa-
tients died (0.4% of the cases): two patients died within
30 days after the procedure for acute exacerbation of IPF
(the coexistence of diffuse alveolar damage and UIP was
confirmed at autopsy) and one patient died two days
after the procedure with thrombotic neoplastic microan-
giopathy/carcinomatous lymphangitis (diagnosis con-
firmed on histology). Characteristics of patients with
Table 5 Correlation between safety outcome and diagnostic yield with number of samples
1–2 samples ≥ 3 samples Fisher’s exact test
Pneumothorax 19/166 (11.4%) 115/532 (21.6%) p 0,0009
Pathological diagnosis 145/168 (86.3%) 469/531 (88.3%) p 0,5030
1 sample 2 samples p
23/34 (67.6%) 122/134 (91.0%) 0,0090
Multidisciplinary diagnosis 20/168 (11.9%) 49/531 (9.2%) p 0,3406
1 sample 2 samples p
23/34 (67.6%) 125/134 (87.0%) 0,0042
Table 6 Differences in terms of safety outcome and diagnostic yield between different sampling strategies
1 site 2 sites Fisher’s exact test
Pneumothorax 64/420 (15.2%) 66/268 (24.6%) p 0,002
Bleeding 51/418 (12.2%) 32/266 (12.0%) p 0,947
Pathological diagnosis 358/422 (84.8%) 247/267 (92.5%) p 0,001
Multidisciplinary diagnosis 373/422 (88.4%) 248/267 (92.9%) p 0,043
1 lobe Different lobes Fisher’s exact test
Pneumothorax 36/166 (21.7%) 30/102 (29.4%) p 0,083
Bleeding 19/166 (11.4%) 13/100 (13%) p 0,7112
Pathological diagnosis 155/166 (93.4%) 92/101 (91.1%) p 0,5081
Multidisciplinary diagnosis 156/166 (93.9%) 92/101 (91.1%) p 0,3967
Upper lobes (a) Lower lobes (a) Fisher’s exact test
Pneumothorax 4/80 (5%) 57/298 (19.1%) p 0,00004
Bleeding 5/78 (6.4%) 42/298 (14.1%) p 0,0270
1.9 probe 2.4 probe Fisher’s exact test
Pneumothorax 2/73 (2.7%) 130/613 (21.2%) p < 0,0001
Bleeding 8/73 (10.9%) 78/611 (12.8%) p 0,6460
Pathological diagnosis 62/73 (84.9%) 541/615 (87.9%) p 0,4936
Multidisciplinary diagnosis 62/63 (84.9%) 557/615 (90.6%) p 0,2014
(a) Cases in which biopsies were performed in the middle lobe or lingula or when it was not possible to establish the exact site of the biopsy were excluded
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more compromised lung function (FVC < 50% predicted
and/or DLCO < 35% predicted) are collected in Table 9.
In this specific sub-group of patients, both pathological
and final multidisciplinary diagnostic yield was lower
(respectively 81 and 84%), whereas there was no signifi-
cant difference in terms of complications; whereas other
factors related to the patient characteristics which
seemed to influence the incidence of complications were
the pre-test radiological pattern and pathological pattern
observed in the biopsy: pneumothorax was much more
frequent in patients with a higher radiological fibrotic
score, evaluated grading the distribution of reticular ab-
normalities, traction bronchiectasis and honeycombing
(p 0.04) and in patients in whom a UIP pattern was
found on histology (28%, p < 0.0001); on the contrary, it
was not possible to find any correlation between deaths
or bleeding and other patients characteristics.
Discussion
Indications for transbronchial lung cryobiopsy in the
diagnosis of diffuse parenchymal lung diseases within
the context of a multidisciplinary discussion are cur-
rently under evaluation, as well as the comparison of its
risks/benefits ratio with that of surgical lung biopsy. How-
ever, reported diagnostic yields (50–100%) and observed
complications of the procedure (eg, rate of pneumothorax
0–30%) vary widely in different centers [2, 5, 6] and the
TLCB technique has not yet been standardized. After the
rapid spread of the technique in the absence of verified
competency and safety standards, in 2018 a statement by
experts in the field has been published, proposing some
recommendations (requisite equipment, personnel, indica-
tions/contraindications, risks and training requirements)
with the aim of facilitating uniform practice and providing
a guide for those wishing to introduce this technique [7].
Series reporting experience of cryobiopsy in the diagnosis
of diffuse parenchymal lung diseases (DPLDs) include a
limited number of patients and it is difficult to compare
different series in terms of sampling strategies, procedural
technical details, diagnostic yield and complications. This
is the largest series of patients with suspected diffuse par-
enchymal lung disease who underwent transbronchial
lung cryobiopsy.
In 630 cases (90.1%) lung tissue obtained from cryo-
biopsy, combined with clinical and radiographic informa-
tion, was sufficient to establish a final multidisciplinary
diagnosis for patient management. Multiple biopsies were
Table 7 Safety outcome




- 29 mild bleeding
- 53 moderate bleeding
- 5 severe bleeding
Other side effects 9 (1.3%)
- 4 transient respiratory failure
- 1 empyema
- 1 seizures




- 2 for AE-IPF
- 1 thrombotic neoplastic
microangiopathy/
carcinomatous lymphangitis
Abbreviations: AE-IPF Acute exacerbation of idiopathic pulmonary fibrosis
Table 8 Correlation between safety profile and baseline lung
function
Pneumothorax No pneumothorax Mann-Whitney test
FVC 80.9% (41–137) 86,6% (38–143) p 0,0079
DLCO 58,2% (25–109) 61,9% (14–129) p 0,0331
Bleeding No bleeding Mann-Whitney test
FVC 85.9% (44–128) 85.6% (38–143) 0,8909
DLCO 61.4% (26–99) 61.4% (18–129) 0,9469
Abbreviations: FVC Forced vital capacity, DLCO Diffusing capacity of the lungs
for carbon monoxide
Table 9 Characteristic of patients with more compromised lung
function (FVC < 50% predicted and/or DLCO < 35% predicted).
Pre-test diagnosis was represented by NSIP (6 cases, 19%), IPF
(6 cases, 19%), sarcoidosis (4 cases, 13%), diffuse neoplastic disease
(4 cases, 13%), HP (3 cases, 10%), other (8 cases, 26%)
Patients characteristics (tot 31) No. (% or
SD)
Median age (SD), y 64 (7.8)
Male, No. (%) 22 (70.9)




Pneumothorax, No. (%) 6 (19.4)
Drained Pneumothorax (among those with
pneumothorax), No. (%)
5 (83.3)
Mild bleeding, No. (%) 2 (6.4)
Moderate bleeding, No. (%) 4 (12.9)
Severe bleeding, No. (%) 0
Other adverse events, No. (%) 1 (3.2) c
2.4 mm probe, No. (%) 26 (83.9)
2 different sites, No. (%) 9 (29.0)
Number of samples (SD), No. 2.3 (1.0)
aPathological diagnoses were UIP (13 cases, 42%), sarcoidosis (3 cases, 10%),
adenocarcinoma (2 cases, 6%), HP (2 cases, 6.5%), OP (2 cases, 6.5%), other (3
cases, 10%).
bMultidisciplinary diagnoses were IPF (14 cases, 45%), sarcoidosis (3 cases,
10%), PPFE (2 cases, 6.5%), adenocarcinoma (2 cases, 6.5%), COP (2 cases,
6.5%), other (3 cases, 10%).
cOther adverse event: empyema; no other complications during or after
the procedure
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usually taken (average number of biopsies per patient was
3.3) to reduce sampling error, as we know that diagnosis
can be influenced by the heterogeneity of the disease and
by the distribution of the parenchymal pathology. The op-
timal number of biopsies has not been established for
cryobiopsy and different strategies adopted to sample lung
tissue are still missing in literature. In our large series,
diagnostic yield was significantly influenced by the num-
ber of samples and the sampling strategy, improving dra-
matically when ≥2 samples were performed (instead of
only one) and when biopsy was obtained in two different
sites (instead of only one site), either from the same lobe
or from different lobes. This is particularly important for
fibrotic lung diseases, in which pathological variability is
more challenging and differential diagnosis could be more
difficult; we observed discordant samples between differ-
ent sites in almost 30% of cases, with a significant increase
in diagnostic yield between one site and two sites. Our
findings confirm and quantify the frequency of inter-lobar
and intra-lobar histologic variability in fibrotic ILD and
confirm the adequacy of cryobiopsy in identifying this
histologic heterogeneity.
Our results confirm a previous study where biopsies
from different segments within the same lobe were asso-
ciated with a higher diagnostic yield compared with bi-
opsies from the same segment [4]. In our series,
cryobiopsy was always performed in different lobes in
patients with significant radiographic inter-lobar hetero-
geneity, while in patients with diffuse radiographic pat-
tern both in the upper and the lower lobes or in patients
with a significant apical-basal gradient, cryobiopsy was
more frequently performed in different segments of the
same one lobe. Prior data on inter-lobar heterogeneity of
DPLDs support the practice to obtain tissue from two
different sites, however, histologic heterogeneity has
been evaluated in the literature until now only in surgi-
cal lung biopsy (SLB) and not in cryobiopsy [8–11]. The
histologic classification in 30% of the patients in our
study could have differed between UIP and NSIP or UIP
and HP if biopsy had been obtained in only one site;
therefore, we think that it is very important to obtain tis-
sue from two different sites, particularly when a clear
apical-basal gradient cannot be identified or when differ-
ent radiological patterns can be observed in different
sites. Significant sampling errors may result from strat-
egies that obtain only one biopsy specimen for ILD.
About 12.2% of cryobiopsies has been considered
non-diagnostic and the reasons included inadequate al-
veolar tissue, normal lung tissue or minimal and nonspe-
cific pathology. The optimal specimen size allowing
pattern recognition has not been established, but some
pathologists suggest that adequate specimens should
measure 5mm in diameter (which is equivalent to the size
of the full field seen with a 4× objective on many
microscopes) [12]. In our study, mean diameter along the
shortest axis was 4.57 +/− 1.18mm (range 0.86–9.81mm).
Regarding complications, pneumothorax is considered
the most frequent event associated with TLCB, although
the rate is significantly variable in the literature, ranging
from less than 1% to almost 30% [2, 5, 13–21]. In our re-
cent meta-analysis, we have already showed that the risk
of pneumothorax can be influenced by procedure-related
factors, like type of sedation/airway control: a higher pro-
portion of pneumothorax occurs among intubated pa-
tients undergoing the procedure under deep sedation with
invasive jet ventilation compared to patients under sed-
ation and spontaneous breathing [2]. In our large series,
pneumothorax occurred in 19.2% of patients, requiring
chest tube drainage in 70% of cases; all patients were
deeply sedated and underwent the procedure intubated
with a rigid tracheoscope during spontaneous breathing.
We have observed that other procedure-related factors
can also influence pneumothorax incidence. Pneumo-
thorax was influenced by the number of samples and was
increased when samples were taken from different sites
instead of a unique site; a higher incidence of pneumo-
thorax was associated with the use of the 2.4mm probe
compared to the 1.9mm probe.
Bleeding during cryobiopsy can also be common [13–
19, 22–25], but it is generally readily controlled endo-
scopically by the use of bronchial blockers and/or use of
rigid tube [1, 2, 16, 23, 25, 26]. All episodes of severe
bleeding reported in the literature were controlled by
placement of bronchial blocker or catheter [24] and no
bleeding-related deaths have been reported after cryo-
biopsy; a recently published report highlights the risk of
potentially life-threatening complications when this pre-
caution is not taken [27]. In our large series, we ob-
served moderate bleeding in 7.6% of patients (requiring
Fogarty balloon bronchial occlusion) and severe bleeding
(resolved with prolonged Fogarty balloon bronchial oc-
clusion, but requiring admission to intensive care unit
and prolonged intubation for < 6 h) in 0.7% of patients.
These results are in accordance with other papers in the
literature [2, 5, 28] and confirm the importance of the
use of Fogarty balloon in preventing severe bleeding. No
cases of fatal bleeding were observed. Bleeding incidence
was not related to the number of samples or sampling
strategy (one vs multiple sites), but there was a numer-
ical increase in the risk of bleeding if biopsy was per-
formed in the lower lobes; one hypothesis that could
explain this phenomenon is that bleeding could be
caused by incidental sampling of venous vessels (how-
ever, it was not possible to discriminate between arteries
and veins in the samples examination). Finally, bleeding
incidence was not related with the probe size.
In our study, the mortality rate was 0.4%: two patients
died within 30 days after the procedure for acute
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exacerbation of IPF (the coexistence of diffuse alveolar
damage and UIP was confirmed at autopsy in both
cases) and one patient died two days after the procedure
with thrombotic neoplastic microangiopathy in the set-
ting of carcinomatous lymphangitis. Apart from one of
these 3 patients, who has been already published [1], the
literature on TLCB documents 9 other deaths related
with the procedure (Table 10). Mortality rate and com-
plications associated with SLB can be influenced by co-
morbidities, recent disease progression [29, 30] and low
baseline lung function values [31]; on the other hand,
the clinical value of trans-bronchial lung cryobiopsy as a
minimally invasive technique in this specific setting (pa-
tients with compromised lung function or significant
co-morbidities who cannot undergo surgical procedures)
has not been yet evaluated. In our large series, the risk
of pneumothorax appeared increased in patients with
more compromised FVC and DLCO, while bleeding was
independent by baseline lung function tests. Fifteen pa-
tients had baseline FVC < 50% predicted and 22 patients
had baseline DLCO < 35% predicted.
There was no difference in terms of diagnostic yield
between 2,4 and 1,9 mm outer diameter cryoprobes, al-
though we know that in order to achieve the same speci-
men size, different freezing times may be necessary (5 s
with the 2.4 mm probe and 7 s with the 1.9 mm probe
should be sufficient in the majority of cases). However,
1,9 mm probe was associated with a significantly re-
duced incidence of pneumothorax compared to the 2,4
mm one and its placement in the lung periphery could
be easier. Nevertheless, these results could be better
confirmed by a prospective study evaluating both diag-
nostic yield and complications in two different random-
ized and homogenous groups of patients with suspected
diffuse parenchymal lung diseases undergoing trans-
bronchial lung cryobiopsy.
Regarding lung function impairment, in the restricted
sub-group of patients with FVC < 50% predicted and/or
DLCO < 35% predicted, both pathological and final
multidisciplinary diagnostic yield was lower, whereas
there was no significant difference in terms of complica-
tions; this data could be due to the fact that these pa-
tients had diseases with more complex and difficult
clinical, pathological and/or radiological presentation or,
most likely, to the fact that in these patients the number
of samples was generally lower and samples were col-
lected more frequently from one single site. TLCB has
been performed safely in a wide age range of patients
(21–87 years), with 56 patients (8%) over 75 years of age,
with no complications, therefore no age limits should be
suggested (giving much more importance to comorbidi-
ties and fitness for anesthesia).
This study, by nature of its retrospective design, has
some limitations. 47 of 699 subjects were found to have
malignancy and 38/699 sarcoidosis, the two conditions
for which conventional transbronchial lung biopsy has a
high diagnostic yield, however, our department is a ter-
tiary care center and we decided to include all patients
referred for suspected DPLD; this can also explain the
high proportion of patients affected by CTD related ILD
(50 patients, 7.2%). The availability of TLCB and its
lower morbidity compared to SLB has broaden the indi-
cations for lung biopsy, including also patients with sus-
pected occult CTD, which can be confirmed by peculiar
histopathological features [14]. This study has no control
group and cryobiopsy was not compared to surgical lung
biopsy within the same population: SLB has never been
validated as a gold standard test and side effects are not
negligible [32]; for these reasons, it was not considered
ethical to propose surgical biopsy to all patients inde-
pendently because of the very favorable diagnostic yield
obtained with cryobiopsy. Finally, diagnostic yield of
cryobiopsy (both pathological and multidisciplinary)
seems higher in this series compared with some previous
data and other groups; these data might be overestimat-
ing the “real world” potential of TLCB and could be in-
fluenced by the expertise of the center; this procedure
requires a learning curve [33] and most multidisciplinary
committees do not have such degree of maximum ex-
pertise, which might easily lead to poorer results, certain
reported controversy, risk-benefit concerns and clinical
frustration. For this reason, it is recommended that cryo-
biopsy be performed by interventional pulmonologists,
appropriately trained in a center with TLCB experience
(familiar with advanced therapeutic bronchoscopic pro-
cedures), and be interpreted by an expert multidisciplin-
ary team [7]. How to define cryobiopsy expertise is not
an easy point and we recognize the need for training
Table 10 Causes of death reported in literature within 30 days
after transbronchial lung cryobiopsy
No Cause of death
3 AE-IPF [1, 35] a
2 Pneumothorax [35] b
1 Lymphangitic carcinomatosis [23]




1 Myocardial infarction aggravated
by AE-IPF [24]
Abbreviations: AE-IPF Acute exacerbation of Idiopathic Pulmonary Fibrosis, OP
Organizing pneumonia
ain two patients, acute exacerbation followed mechanical ventilation, necessary
for respiratory failure caused by severe bleeding (no balloon or blocker used)
bone patient had diffuse lung adenocarcinoma and one patient had right
upper lobe cavity and died from septic shock after drained
iatrogenic pneumothorax.
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programs and the establishment of competency and
quality standards for the procedure itself, in order to ex-
pand the knowledge and use of this technique, overcome
the current vicious circle situation, clarify real expecta-
tions as well as the role of TLCB in clinical practice.
Conclusion
Despite the lack of standardized procedure and approach
and the heterogeneous incidence of complications in the
literature, our large series confirms that lung cryobiopsy
can obtain an adequate sample with a specific diagnosis
in the vast majority of cases, including fibrotic lung dis-
eases (eg. chronic HP, IPF, NSIP), with a very low overall
mortality. We described some sampling strategies which
seem to be associated with a higher diagnostic yield and
a favorable risk/benefit ratio: 1) it is advisable to obtain
two samples from two different sites in order to enhance
the diagnostic yield (e.g. from different lobes in case of
inter-lobar radiographic heterogeneity) and even taking
samples from different segments in the same lobe may
be rise the diagnostic yield, as previously demonstrated
[4]; 2) it is advisable to use only 1.9 mm probe (2.4 mm
probe may be associated with a higher rate of pneumo-
thorax and more technical problems without signifi-
cantly increasing the diagnostic yield); 3) sampling from
lower lobes may be associated to a higher rate of compli-
cations (both bleeding and pneumothorax) than in upper
lobes; 4) the risk of pneumothorax also increases in case
of impaired lung function (FVC < 50% and DLCO <
35%) and sampling two sites; 5) it is preferable to intub-
ate the patients (either with rigid tracheoscope or flex-
ible tube), always using bronchial blockers or catheters
[34]. The simplicity and low morbidity of cryobiopsy can
potentially broaden the indications of this procedure
compared to SLB, such as in diffuse parenchymal lung
disease in patients with suspected occult collagen vascu-
lar disease, patients with more compromised baseline
lung function or even in patients with a typical radio-
logical UIP pattern, with the aim of collecting more in-
formative data. However, low pulmonary function values
have a prognostic impact and the clinical value of TLCB
in this setting is not yet known; safety in the most severe
group of patients would require further demonstration.
Finally, the possible role and risk-benefit of TBLC in the
management of patients with typical UIP pattern re-
quires specific studies since in this group of patients, bi-
opsy may be necessary to make a therapeutic decision
only in very selected cases.
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